Did you have any side effects with this medicine?
What is Ciprofloxacin Alvia?
Treating ear infections caused by certain bacteria.
Ciprofloxacin Alvia ear drops is a quinolone antibiotic. It works by killing sensitive bacteria.
Ciprofloxacin Alvia indications
Ciprofloxacin Alvia Injection, USP in 5% Dextrose is indicated for the treatment of infections caused by susceptible isolates of the designated microorganisms in the conditions and patient populations listed below when the intravenous administration is needed.
Urinary Tract Infections
Ciprofloxacin Alvia Injection, USP in 5% Dextrose is indicated in adult patients for treatment of urinary tract infections caused by Escherichia coli, Klebsiella pneumoniae, Enterobacter cloacae, Serratia marcescens, Proteus mirabilis, Providencia rettgeri, Morganella morganii, Citrobacter koseri, Citrobacter freundii, Pseudomonas aeruginosa, methicillin-susceptible Staphylococcus epidermidis, Staphylococcus saprophyticus, or Enterococcus faecalis.
Lower Respiratory Tract Infections
Ciprofloxacin Alvia Injection, USP in 5% Dextrose is indicated in adult patients for treatment of lower respiratory tract infections caused by Escherichia coli, Klebsiella pneumoniae, Enterobacter cloacae, Proteus mirabilis, Pseudomonas aeruginosa, Haemophilus influenzae, Haemophilus parainfluenzae, or Streptococcus pneumoniae.* Also, Ciprofloxacin Alvia Injection, USP in 5% Dextrose is indicated for the treatment of acute exacerbations of chronic bronchitis caused by Moraxella catarrhalis.
Ciprofloxacin Alvia Injection, USP in 5% Dextrose is indicated in adult patients for treatment of nosocomial pneumonia caused by Haemophilus influenzae or Klebsiella pneumoniae.
Skin and Skin Structure Infections
Ciprofloxacin Alvia Injection, USP in 5% Dextrose is indicated in adult patients for treatment of skin and skin structure infections caused by Escherichia coli, Klebsiella pneumoniae, Enterobacter cloacae, Proteus mirabilis, Proteus vulgaris, Providencia stuartii, Morganella morganii, Citrobacter freundii, Pseudomonas aeruginosa, methicillin susceptible Staphylococcus aureus, methicillin-susceptible Staphylococcus epidermidis, or Streptococcus pyogenes.
Bone and Joint Infections
Ciprofloxacin Alvia Injection, USP in 5% Dextrose is indicated in adult patients for treatment of bone and joint infections caused by Enterobacter cloacae, Serratia marcescens, or Pseudomonas aeruginosa.
Complicated Intra-Abdominal Infections
Ciprofloxacin Alvia Injection, USP in 5% Dextrose is indicated in adult patients for treatment of complicated intra-abdominal infections (used in combination with metronidazole) caused by Escherichia coli, Pseudomonas aeruginosa, Proteus mirabilis, Klebsiella pneumoniae, or Bacteroides fragilis.
Ciprofloxacin Alvia Injection, USP in 5% Dextrose is indicated in adult patients for treatment of acute sinusitis caused by Haemophilus influenzae, Streptococcus pneumoniae, or Moraxella catarrhalis.
Chronic Bacterial Prostatitis
Ciprofloxacin Alvia Injection, USP in 5% Dextrose is indicated in adult patients for treatment of chronic bacterial prostatitis caused by Escherichia coli or Proteus mirabilis.
Empirical Therapy for Febrile Neutropenic Patients
Ciprofloxacin Alvia Injection, USP in 5% Dextrose is indicated in adult patients for the treatment of febrile neutropenia in combination with piperacillin sodium.
Complicated Urinary Tract Infections and Pyelonephritis
Ciprofloxacin Alvia Injection, USP in 5% Dextrose is indicated in pediatric patients one to 17 years of age for treatment of complicated urinary tract infections (cUTI) and pyelonephritis due to Escherichia coli.
Inhalational Anthrax (post-exposure)
Ciprofloxacin Alvia Injection, USP in 5% Dextrose is indicated in adults and pediatric patients from birth to 17 years of age for treatment of inhalational anthrax (post-exposure) to reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis.
Ciprofloxacin Alvia serum concentrations achieved in humans served as a surrogate endpoint reasonably likely to predict clinical benefit and provided the initial basis for approval of this indication.1 Supportive clinical information for Ciprofloxacin Alvia for anthrax post-exposure prophylaxis was obtained during the anthrax bioterror attacks of October 2001.
Ciprofloxacin Alvia Injection, USP in 5% Dextrose is indicated for treatment of plague, including pneumonic and septicemic plague, due to Yersinia pestis (Y. pestis) and prophylaxis for plague in adults and pediatric patients from birth to 17 years of age. Efficacy studies of Ciprofloxacin Alvia could not be conducted in humans with plague for feasibility reasons. Therefore this indication is based on an efficacy study conducted in animals only.
Limitations of Use
Use in Pediatric Patients
Although effective in clinical trials, Ciprofloxacin Alvia is not a drug of first choice in the pediatric population due to an increased incidence of adverse events compared to controls, including events related to joints and/or surrounding tissues. Ciprofloxacin Alvia Injection, USP in 5% Dextrose, like other fluoroquinolones, is associated with arthropathy and histopathological changes in weight-bearing joints of juvenile animals.
Lower Respiratory Tract Infections
Ciprofloxacin Alvia Injection, USP in 5% Dextrose is not a drug of first choice in the treatment of presumed or confirmed pneumonia secondary to Streptococcus pneumoniae.
To reduce the development of drug-resistant bacteria and maintain the effectiveness of Ciprofloxacin Alvia Injection, USP in 5% Dextrose and other antibacterial drugs, Ciprofloxacin Alvia Injection, USP in 5% Dextrose should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.
If anaerobic organisms are suspected of contributing to the infection, appropriate therapy should be administered. Appropriate culture and susceptibility tests should be performed before treatment in order to isolate and identify organisms causing infection and to determine their susceptibility to Ciprofloxacin Alvia. Therapy with Ciprofloxacin Alvia Injection, USP in 5% Dextrose may be initiated before results of these tests are known; once results become available appropriate therapy should be continued. As with other drugs, some isolates of Pseudomonas aeruginosa may develop resistance fairly rapidly during treatment with Ciprofloxacin Alvia. Culture and susceptibility testing performed periodically during therapy will provide information not only on the therapeutic effect of the antimicrobial agent but also on the possible emergence of bacterial resistance.
How should I use Ciprofloxacin Alvia?
Use Ciprofloxacin Alvia as directed by your doctor. Check the label on the medicine for exact dosing instructions.
- Ciprofloxacin Alvia comes with an extra patient information sheet called a Medication Guide. Read it carefully. Read it again each time you get Ciprofloxacin Alvia refilled.
- Take Ciprofloxacin Alvia by mouth with the evening meal, unless directed otherwise by your doctor.
- Swallow Ciprofloxacin Alvia whole with a full glass of water. Do not break, crush, or chew before swallowing. If you cannot swallow Ciprofloxacin Alvia whole, tell your doctor.
- Drinking extra fluids while you are taking Ciprofloxacin Alvia is recommended. Check with your doctor for instructions.
- If you also take any products containing magnesium, aluminum, calcium, iron, or zinc (eg, antacids, quinapril, vitamins/minerals); didanosine; sucralfate; or bismuth subsalicylate, do not take them within 6 hours before or 2 hours after taking Ciprofloxacin Alvia. Check with your doctor if you have questions.
- If you also take sevelamer, do not take it within 4 hours before or after taking Ciprofloxacin Alvia. Check with your doctor if you have questions.
- To clear up your infection completely, take Ciprofloxacin Alvia for the full course of treatment. Keep taking it even if you feel better in a few days.
- Avoid taking Ciprofloxacin Alvia with milk or milk products (eg, calcium-enriched juice, yogurt) by themselves. However, taking Ciprofloxacin Alvia as part of a full meal that contains milk or milk products is permitted.
- If you miss a dose of Ciprofloxacin Alvia, take it as soon as possible if you remember on the same day. If you do not remember until the next day, skip the missed dose and go back to your regular dosing schedule. Do not take 2 doses on the same day.
Ask your health care provider any questions you may have about how to use Ciprofloxacin Alvia.
Uses of Ciprofloxacin Alvia in details
Ciprofloxacin Alvia is used to treat wide range of bacterial infections including lung or respiratory tract infections, eye infection, bladder and kidney infections, reproductive tract infections, skin and soft tissue infections and bone and joint infections.
Ciprofloxacin Alvia description
Ciprofloxacin Alvia is a drug used to treat bacterial infections. It is a second generation fluoroquinolone antibacterial. It kills bacteria by interfering with the enzymes that cause DNA to rewind after being copied, which stops DNA and protein synthesis.
Ciprofloxacin Alvia is marketed worldwide with over three hundred different brand names. In the United States, Canada and the UK, it is marketed as Ciloxan, Cipro, Cipro XR, Cipro XL Ciproxin and, most recently, Proquin. In Mexico it is available over the counter and marketed under the names Ciproflox or Ciprofloxacino. In Ecuador it is available and marketed under the name Cidrax. In Nigeria it is sold as Ciprotab while in Bangladesh it is marketed as Tablets and Microcapsules for Suspension by numerous companies, one of which is by Edruc Limited as Cipron. Additionally, Ciprofloxacin Alvia is available as a generic drug under a variety of different brand names and is also available for limited use in veterinary medicine.
Ciprofloxacin Alvia was first patented in 1983 by Bayer A.G. and subsequently approved by the United States Food and Drug Administration (FDA) in 1987.Ciprofloxacin Alvia has 12 F.D.A.-approved human uses and other veterinary uses, but it is often used for non-approved uses (off-label).
Ciprofloxacin Alvia interacts with other drugs, herbal and natural supplements, and thyroid medications.
Active ingredient matches for Ciprofloxacin Alvia:
Ciprofloxacin in Greece.
- DailyMed. "CIPROFLOXACIN; DEXAMETHASONE: DailyMed provides trustworthy information about marketed drugs in the United States. DailyMed is the official provider of FDA label information (package inserts).". https://dailymed.nlm.nih.gov/dailymed/se... (accessed September 18, 2017).
- Wikipedia. "ciprofloxacin: Link to the compound information in Wikipedia.". https://en.wikipedia.org/wiki/Ciprofloxa... (accessed September 18, 2017).
- PubChem. "ciprofloxacin". https://pubchem.ncbi.nlm.nih.gov/compoun... (accessed September 18, 2017).
- FDA Orange Book. "CIPROFLOXACIN; CIPROFLOXACIN HYDROCHLORIDE: The publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the List, commonly known as the Orange Book), identifies drug products approved on the basis of safety and effectiveness by the Food and Drug Administration (FDA) under the Federal Food, Drug, and Cosmetic Act (the Act).". https://www.fda.gov/Drugs/InformationOnD... (accessed September 18, 2017).
ReviewsThe results of a survey conducted on ndrugs.com for Ciprofloxacin Alvia are given in detail below. The results of the survey conducted are based on the impressions and views of the website users and consumers taking Ciprofloxacin Alvia. We implore you to kindly base your medical condition or therapeutic choices on the result or test conducted by a physician or licensed medical practitioners.
Consumer reported usefulNo survey data has been collected yet
Consumer reported price estimatesNo survey data has been collected yet
Consumer reported time for resultsNo survey data has been collected yet
Consumer reported ageNo survey data has been collected yet